journal article·2024-08Open access

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Yue Wu, Xin Li, Xueyu Fu, Xiaomin Huang, Shenrong Zhang, Nan Zhao, Xiaowei Ma, Qimanguli Saiding, Mei Yang, Wei Tao, Xingtao Zhou, Jinhai Huang

Advanced Science· Volume 11· Issue 32

Abstract

Abstract Funduscopic diseases, including diabetic retinopathy (DR) and age‐related macular degeneration (AMD), significantly impact global visual health, leading to impaired vision and irreversible blindness. Delivering drugs to the posterior segment of the eye remains a challenge due to the presence of multiple physiological and anatomical barriers. Conventional drug delivery methods often prove ineffective and may cause side effects. Nanomaterials, characterized by their small size, large surface area, tunable properties, and biocompatibility, enhance the permeability, stability, and targeting of drugs. Ocular nanomaterials encompass a wide range, including lipid nanomaterials, polymer nanomaterials, metal nanomaterials, carbon nanomaterials, quantum dot nanomaterials, and so on. These innovative materials, often combined with hydrogels and exosomes, are engineered to address multiple mechanisms, including macrophage polarization, reactive oxygen species (ROS) scavenging, and anti‐vascular endothelial growth factor (VEGF). Compared to conventional modalities, nanomedicines achieve regulated and sustained delivery, reduced administration frequency, prolonged drug action, and minimized side effects. This study delves into the obstacles encountered in drug delivery to the posterior segment and highlights the progress facilitated by nanomedicine. Prospectively, these findings pave the way for next‐generation ocular drug delivery systems and deeper clinical research, aiming to refine treatments, alleviate the burden on patients, and ultimately improve visual health globally.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Corneal Surgery and Treatments · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; NHC Key Laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases Chinese Academy of Medical Sciences Shanghai 200031 China

Shanghai Research Center of Ophthalmology and Optometry Shanghai 200031 China

Wenzhou Medical University Wenzhou Zhejiang 325035 China

Center for Nanomedicine and Department of Anesthesiology Brigham and Women's Hospital, Harvard Medical School Boston MA 02115 USA

Funding

National Natural Science Foundation of China

References (100+)

Show source-provided references
1. 10.1126/sciadv.abq310410.1126/sciadv.abq3104 ↗
2. 10.2174/138945012166620042810173810.2174/1389450121666200428101738 ↗
3. 10.1126/sciadv.aba745710.1126/sciadv.aba7457 ↗
4. 10.1016/S0140-6736(17)30979-010.1016/S0140-6736(17)30979-0 ↗
5. 10.1016/j.ophtha.2020.04.01710.1016/j.ophtha.2020.04.017 ↗
6. 10.2174/221173851066622080610261210.2174/2211738510666220806102612 ↗
7. 10.1002/advs.20200369910.1002/advs.202003699 ↗
8. 10.3390/molecules2716508910.3390/molecules27165089 ↗
9. 10.1186/s40662-016-0063-510.1186/s40662-016-0063-5 ↗
10. 10.1001/archophthalmol.2009.5810.1001/archophthalmol.2009.58 ↗
11. 10.3390/cells1009248310.3390/cells10092483 ↗
12. 10.1136/bjophthalmol-2015-30697210.1136/bjophthalmol-2015-306972 ↗
13. 10.1016/j.gendis.2021.02.00910.1016/j.gendis.2021.02.009 ↗
14. 10.1016/j.ophtha.2019.09.02810.1016/j.ophtha.2019.09.028 ↗
15. 10.1155/2019/494082510.1155/2019/4940825 ↗
16. Agriodimos G. · Stud. Health Technol. Inform. · 2021 · 287 · 167
17. 10.1016/S0161-6420(13)38011-710.1016/S0161-6420(13)38011-7 ↗
18. 10.1056/NEJM19990826341090710.1056/NEJM199908263410907 ↗
19. 10.1097/ICU.000000000000076010.1097/ICU.0000000000000760 ↗
20. 10.1016/j.survophthal.2018.04.00510.1016/j.survophthal.2018.04.005 ↗
21. 10.1016/j.preteyeres.2021.10096410.1016/j.preteyeres.2021.100964 ↗
22. 10.1167/iovs.62.5.510.1167/iovs.62.5.5 ↗
23. 10.1136/bjo.2005.07471610.1136/bjo.2005.074716 ↗
24. 10.1016/0002-9394(81)90170-710.1016/0002-9394(81)90170-7 ↗
25. 10.1038/eye.2012.9710.1038/eye.2012.97 ↗
26. 10.1016/j.ophtha.2014.05.01310.1016/j.ophtha.2014.05.013 ↗
27. Sena D. F. · Cochrane Database Syst. Rev. · 2017 · 2017
28. 10.1001/archopht.117.11.154010.1001/archopht.117.11.1540 ↗
29. Sena D. F. · 2007 · CD006539
30. 10.3390/genes1110112010.3390/genes11101120 ↗
31. 10.1097/IIO.000000000000025610.1097/IIO.0000000000000256 ↗
32. Renton W. D. · Cochrane Database Syst. Rev. · 2022 · 10
33. 10.1038/s41388-017-0050-x10.1038/s41388-017-0050-x ↗
34. 10.1007/s12098-017-2395-010.1007/s12098-017-2395-0 ↗
35. 10.1038/nrd.2015.1710.1038/nrd.2015.17 ↗
36. 10.1016/0006-291X(89)92678-810.1016/0006-291X(89)92678-8 ↗
37. 10.1016/j.cell.2019.01.02110.1016/j.cell.2019.01.021 ↗
38. 10.1021/acs.nanolett.3c0274310.1021/acs.nanolett.3c02743 ↗
39. 10.1021/acs.chemrev.7b0016110.1021/acs.chemrev.7b00161 ↗
40. 10.1038/s41586-023-06002-x10.1038/s41586-023-06002-x ↗
41. 10.1007/s00424-017-1947-510.1007/s00424-017-1947-5 ↗
42. 10.1002/path.413310.1002/path.4133 ↗
43. 10.1007/s13577-021-00580-610.1007/s13577-021-00580-6 ↗
44. 10.3390/ijms2410876310.3390/ijms24108763 ↗
45. 10.1523/JNEUROSCI.0190-15.201510.1523/JNEUROSCI.0190-15.2015 ↗
46. 10.3390/cells1003068710.3390/cells10030687 ↗
47. 10.1016/j.bmc.2007.01.01110.1016/j.bmc.2007.01.011 ↗
48. 10.1189/jlb.060733810.1189/jlb.0607338 ↗
49. 10.1186/s12885-021-07860-210.1186/s12885-021-07860-2 ↗
50. 10.1096/fj.03-0113fje10.1096/fj.03-0113fje ↗
51. Rupenthal I. · 2010
52. 10.1089/jop.2019.010910.1089/jop.2019.0109 ↗
53. 10.1016/j.cis.2020.10234210.1016/j.cis.2020.102342 ↗
54. 10.5301/EJO.2010.605110.5301/EJO.2010.6051 ↗
55. 10.3390/pharmaceutics1305070110.3390/pharmaceutics13050701 ↗
56. 10.1016/j.exer.2022.10910110.1016/j.exer.2022.109101 ↗
57. 10.1002/adma.20230243110.1002/adma.202302431 ↗
58. 10.1093/imammb/dqp01910.1093/imammb/dqp019 ↗
59. 10.1016/j.ijpharm.2021.12092410.1016/j.ijpharm.2021.120924 ↗
60. 10.2174/13816120978892388610.2174/138161209788923886 ↗
61. 10.1021/js980259410.1021/js9802594 ↗
62. Olsen T. W. · Invest. Ophthalmol. Visual Sci. · 1995 · 36 · 1893
63. 10.1016/j.preteyeres.2019.10077310.1016/j.preteyeres.2019.100773 ↗
64. 10.1016/j.preteyeres.2010.04.00310.1016/j.preteyeres.2010.04.003 ↗
65. 10.1016/j.disamonth.2020.10104310.1016/j.disamonth.2020.101043 ↗
66. 10.1517/17425247.3.2.27510.1517/17425247.3.2.275 ↗
67. 10.1016/j.drudis.2007.11.00210.1016/j.drudis.2007.11.002 ↗
68. 10.1016/B978-0-12-816434-1.00010-310.1016/B978-0-12-816434-1.00010-3 ↗
69. 10.1111/febs.1633010.1111/febs.16330 ↗
70. 10.5301/EJO.2010.604910.5301/EJO.2010.6049 ↗
71. 10.3390/ph1311035110.3390/ph13110351 ↗
72. 10.1016/j.ijpharm.2021.12057110.1016/j.ijpharm.2021.120571 ↗
73. 10.2174/15701631179679906210.2174/157016311796799062 ↗
74. 10.2174/187221131466619122411521110.2174/1872211314666191224115211 ↗
75. 10.1016/j.ijpharm.2005.04.02910.1016/j.ijpharm.2005.04.029 ↗
76. 10.3390/ijms1910297710.3390/ijms19102977 ↗
77. 10.1007/s00210-022-02287-310.1007/s00210-022-02287-3 ↗
78. 10.1089/jop.2017.009910.1089/jop.2017.0099 ↗
79. 10.1080/10717544.2019.157112210.1080/10717544.2019.1571122 ↗
80. 10.1089/jop.2018.010110.1089/jop.2018.0101 ↗
81. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
82. 10.1016/j.jconrel.2019.04.01510.1016/j.jconrel.2019.04.015 ↗
83. 10.1126/sciadv.add462310.1126/sciadv.add4623 ↗
84. Mishra V. · Pharm. · 2018 · 10 · 191
85. 10.1016/S0169-409X(01)00105-310.1016/S0169-409X(01)00105-3 ↗
86. 10.1007/s13346-020-00733-410.1007/s13346-020-00733-4 ↗
87. 10.1016/j.ejpb.2016.10.01610.1016/j.ejpb.2016.10.016 ↗
88. 10.1016/j.phrs.2016.07.04210.1016/j.phrs.2016.07.042 ↗
89. 10.2217/nnm-2018-027810.2217/nnm-2018-0278 ↗
90. 10.1016/j.msec.2019.03.06010.1016/j.msec.2019.03.060 ↗
91. Bonilla L. · Pharm. · 2021 · 14 · 90
92. 10.1016/j.jddst.2019.02.01710.1016/j.jddst.2019.02.017 ↗
93. 10.1080/0265204001000036110.1080/02652040010000361 ↗
94. 10.1166/jnn.2020.1856910.1166/jnn.2020.18569 ↗
95. 10.1016/j.biomaterials.2021.12068210.1016/j.biomaterials.2021.120682 ↗
96. 10.1016/j.biopha.2018.08.09210.1016/j.biopha.2018.08.092 ↗
97. 10.1016/j.ijpharm.2019.04.01210.1016/j.ijpharm.2019.04.012 ↗
98. 10.1016/j.jconrel.2019.01.01210.1016/j.jconrel.2019.01.012 ↗
99. 10.1016/j.ijpharm.2018.07.01310.1016/j.ijpharm.2018.07.013 ↗
100. 10.1089/jop.2019.007410.1089/jop.2019.0074 ↗